• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • The Syncona platform
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
    • Aligning with UN SDGs
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment case
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

News

Show
  • Sustainability
  • Financial
  • Operating News
news from
  • all companies
  • Syncona
  • all Cell therapy companies
  • Autolus
  • Achilles Therapeutics
  • Quell Therapeutics
  • Resolution Therapeutics
  • Neogene Therapeutics
  • Clade Therapeutics
  • all Gene therapy companies
  • Freeline Therapeutics
  • SwanBio Therapeutics
  • Purespring Therapeutics
  • all Biologics companies
  • Anaveon
  • all Small molecule companies
  • OMass Therapeutics
12.05.22

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

  • Operating News
  • Cell therapy
  • Autolus
05.05.22

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

  • Cell therapy
  • Autolus
02.05.22

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

  • Operating News
  • Cell therapy
  • Autolus
25.04.22

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

  • Operating News
  • Cell therapy
  • Autolus
25.04.22

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

  • Operating News
  • Cell therapy
  • Autolus
31.03.22

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

  • Operating News
  • Cell therapy
  • Autolus
Load more

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

  • RNS alerts
  • Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR
contact@synconaltd.com

  • About us
  • Our people
  • Portfolio
  • Sustainability
  • News and Insights
  • Investors
  • Contact
  • Copyright © Syncona 2022
  • Accessibility
  • Privacy & cookies
  • Employee privacy notice
  • Third party privacy notice
  • Regulatory publications
  • Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay
  • About us
    • About us
    • Who we are
    • Our model
    • The Syncona platform
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
    • Aligning with UN SDGs
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment case
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
GBX 177.00
Change: -2.80 (-1.56%)

Search